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Abstract 
This thesis is the result of four months of an internship, as a part of the final year of the 
Masters in Veterinary Medicine. It was divided between the Queen Mother Hospital for 
Animals – Royal Veterinary College, Hertfordshire, London United Kingdom, and the 
Veterinary Referral Hospital of Montenegro, Porto, Portugal.  
During my time in the United Kingdom, I developed an interest in the area of 
Anaesthesia/Analgesia and given the importance of pain syndromes in the clinical setting, I 
thought that would be a good topic. In the analgesia department, there are many branches to 
follow like neuromuscular blocks, pre and post-operative analgesia, among others. I thought it 
would be interesting to investigate the area of intra-operative analgesia because in some cases, 
even after the pre-operative analgesia and/or neuromuscular or regional blocks, the surgical 
stimulus is still capable of inducing pain and it should be managed while still in surgery.  
Throughout this thesis, I will present a bibliographic review on the subject of pain and 
its pathophysiology, which will provide a good basis for understanding the concept of analgesia. 
Moreover, I will present a simple approach to the various forms of analgesia that I witnessed 
during my internship, their mechanisms of action, and their use in different surgeries. Finally, 
I will present a couple of cases I had the opportunity of participating in during my stay at the 
Queen Mother Hospital for Animals, hoping to demonstrate the optimal use of analgesic drugs 
during surgical procedures.  
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I - Introduction 
This dissertation arose from my time spent as an intern in the Queen Mother Hospital 
for Animals, Royal Veterinary College, London United Kingdom, and the Veterinary Referral 
Hospital of Montenegro, Porto, Portugal.  
I have been in the Queen Mother Hospital for Animals with the Anesthesia and 
Analgesia service before for two weeks during Easter. It was during that time that Doctor 
Christopher Seymour kindly offered me the opportunity to do my internship there. During my 
time at the Queen Mother Hospital for Animals I had the opportunity to follow the cases 
involving sedation and/or general anesthesia, assist and participate in the whole process of 
anesthesia/analgesia, assessing the patients and analysing the best plan for them, taking care of 
critical care animals and many other tasks. For my internship, I had the goal to obtain 
knowledge, hability and dexteriry and I choose the Veterinary Referral Hospital of Montenegro 
to complement that experience. In the Veterinary Referral Hospital of Montenegro I had the 
chance to be responsible for internees, administer medications, perform general exams, contact 
with the owners, assist clinical and referral consults as well as diagnostic procedures and 
surgeries.  
I could have done a practical case report but I decided to write about a theme that was 
related to my internship experience. A masters thesis always involves scientific and research 
work but I wanted to take into account my overall learning path and because of that, with the 
help and idea of Professor Pablo Payo Puente, I started an online platform – blog – about my 
internship. It contains some of the cases I had the opportunity to follow and more important, it 
reflects my personal experience: what I felt, what I learned in a personal and professional level. 
I believe this type of reflexion is important to consolidate the learning process and to improve 
future experiences (see Figure 1, Appendix I).  
Pain is a growing concern both in human and in animal care. Particularly in animals, the 
presence of pain is not always obvious but can be reason behind many clinical signs. In surgical 
procedures, pain be associated with the trauma or disease itself or with surgical stimulation. 
Nevertheless, surgical stimulus should not serve as an excuse for pain in animals under 
anaesthesia in surgery. For this reason, the next pages will present an approach on this complex 
subject of pain and what can be used during surgery to manage it. 
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II - Bibliographic review 
1 - Definition of pain 
Sir Charles Sherrington in 1900 was one of the first modern scientists to define pain as 
the psychical adjunct to an imperative protective reflex (Lamont et al. 2000). This definition 
underlines the primitive origin of pain, which is the motor response oriented towards removing 
tissue from potentially damaging insults. More recently, the International Association for the 
Study of Pain has proposed a different definition: pain is an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage (Lamont et al. 2000, Lemke & Creighton 2010). In this definition, the subjective 
emotional and affective components are taken into consideration. In a way, pain differs from 
other sensory modalities since diverse stimuli are capable of initializing a complex response.  
Since animals are not capable of verbally communicating the painful experience, pain 
may be best described as an aversive sensory and emotional experience representing awareness 
of damage or threat to the integrity of its tissues, producing a change in physiology and 
behaviour directed to reduce or avoid the damage, reduce the likelihood of recurrence and 
promote recovery (Price & Nolan 2008). 
There are actually 3 different types of pain, although not everyone makes the distinction 
(see Figure 2, Appendix I). First, there is the nociceptive or physiological pain - a conscious 
experience of acute pain which detects and minimizes contact with noxious stimuli (Woolf 
2010). It is essential as a warning pathway, protecting the system. This type of pain only detects 
potentially tissue-damaging noxious stimuli, such as heat or mechanical force, similar to when 
we touch a sharp object. Physiological pain is experienced by animals on a regular basis. An 
important definition is pain threshold - it refers to the minimum intensity at which a stimulus is 
perceived as painful; it is relatively constant for most individuals within a species (Greene 
2002). Nociceptive pain requires a high-threshold noxious input and it is well-localized. The 
response to this high-threshold pain is the withdrawal reflex and all the sensations that come 
with it. Although nociceptive pain is essential as a warning system, in surgery there is 
continuous noxious stimulation and because of that it may need to be suppressed by anaesthetics 
or analgesics. This is where the veterinarian plays an important role. However, the lack of 
nociceptive pain is not a desirable situation (Woolf 2010): even when analgesics are given after 
or during a clinical procedure, clinicians should not decrease nociceptive pain so much that its 
protective role is lost by the therapy. There should always be a level of pain capable of 
maintaining body integrity (Woolf 2010). 
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Related to nociceptive pain is the second type of pain – inflammatory pain. This pain 
acts after the tissue damage by healing the injured body part. Following tissue damage, the 
sensitivity of the affected area increases so that normally innocuous stimuli are perceived as 
painful (Price & Nolan 2008). Thus, having this kind of pain avoids further damage to the 
tissues and promotes recovery since it discourages physical contact and movement (Woolf 
2010). Inflammatory pain happens secondary to the activation of the immune system and 
although it has a protective role it still needs to be decreased in patients with ongoing 
inflammation (Woolf 2010). After the tissue heals, these changes in nociception will reverse. If 
the inflammation persists, the pain will persist as part of a chronic condition (Price & Nolan 
2008).  
The third type of pain is a result of an abnormal nervous system and it is called 
pathological or neuropathic pain. This is not protective or adaptive but is a result of damage to 
the nervous system or other system dysfunctions (Woolf 2010). Changes in the peripheral 
nervous system, spinal cord, brainstem and brain (Price & Nolan 2008) can disrupt 
neurochemistry and neuron transmission in such a way that normally non-noxious stimuli can 
be perceived as painful.  
Inflammatory pain is the most common type of perioperative pain (Lemke & Creighton 
2010), although neuropathic pain may also occur in some patients and both can happen as the 
result of surgical trauma (Lemke 2004). Understanding the mechanisms of inflammatory pain 
forms the basis for effective multimodal analgesic therapy (Lemke & Creighton 2010). 
An important breakthrough to understanding the physiology of pain is recognising that 
the pain which occurs after most noxious stimuli is physiologic or nociceptive pain: this is 
usually protective and distinct from the pain resulting from damage to tissues or nerves (Lamont 
et al. 2000). This protective mechanism is facilitated by a specialized network of nociceptors 
and primary sensory neurons that encode the intensity, duration and quality of noxious stimuli 
and, by the well-organised projections to the spinal cord, their location. The extrapolation of 
the physiologic model of pain to the clinical setting has several limitations but a better 
understanding of the basic pain pathways is essential (Lamont et al. 2000).  
2 - Pathophysiology of pain - Nociception 
Managing operative pain effectively is a very important task that clinical veterinarians 
perform on a daily basis. A basic understanding of the pathophysiology of pain is needed before 
10 
 
practitioners can manage perioperative pain in a safe and effective manner. With this 
understanding, the principles of pain management can be appreciated, and analgesic drugs and 
techniques can be selected on a more rational basis (Lemke 2004). 
The physiologic component of pain is named nociception – the neural response that 
starts with the detection of a noxious stimulus and completed by the transmission of encoded 
information to the brain. It consists of different sequential processes: transduction , transmission 
and modulation of neural signals generated in response to a noxious stimulus (Lamont et al. 
2000). This will lead to the perception of pain. 
In a simple approach, this pathway can be considered as a three-neuron chain of 
transmission where the first neuron originates in the periphery and ascends to the spinal cord, 
the second order neuron ascends the spinal cord and the third one projects to the cerebral cortex 
(Lamont et al. 2000). The 1st neuron is the afferent neuron and it is responsible for transduction 
of the noxious stimuli and conducting the signals from the peripheral tissues to neurons in the 
dorsal horn of the spinal cord (Lemke & Creighton 2010). The 2nd neuron in the chain is the 
projection neuron – it receives input from the afferent neurons and projects the information to 
neurons in the medulla, pons, midbrain, thalamus and hypothalamus (Lemke & Creighton 
2010). The 3rd order neurons are supraspinal neurons, which integrate signals from the previous 
neurons and project the information to the subcortical and cortical areas where pain is finally 
perceived (Lemke 2004, Lemke & Creighton 2010).  
The first process of nociception involves specialized nerve endings – nociceptors. They  
are non-selective ion channels (Lamont 2008) that encode mechanical, chemical or thermal 
energy into electric impulses and exist as nerve endings of afferent neurons. Nociceptors signal 
potential tissue injury and because of that, preserve tissue homeostasis (Lamont et al. 2000). 
Once activated by those mechanical, thermal and chemical stimuli, nociceptors open their 
channels and sodium and calcium ions flow into the nociceptor peripheral terminal, producing 
a current that depolarizes the membrane (Lamont 2008). These neurons have axons that project 
both peripherally to somatic and visceral tissues and centrally to the dorsal horn of the spinal 
cord (Lemke & Creighton 2010). The action potentials discussed earlier are conducted from the 
periphery (nociceptors) to the central nervous system through axons of primary afferent 
nociceptive fibers (Lamont 2008). Somatic tissues have a higher density of nociceptive nerve 
fibers and smaller receptive fields; visceral tissues have a lower density of nociceptive nerve 
fibers and larger receptive fields (Lemke & Creighton 2010). 
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Primary afferent nerve fibers conduct information from those free nerve endings to their 
central location (Price & Nolan 2008). Neurophysiological studies have classified primary 
afferent nerve fibers into two categories according to their associated nerve fibers and 
sensitivities (Lamont et al. 2000): A-fiber and C-fiber nociceptors (see Figure 3, Appendix I). 
A-fiber nociceptors are further classified into A-β and A-δ fibers. The first respond to non-
noxious stimuli (touch) but not directly to noxious stimuli (Lemke 2004). A-δ fibers are small, 
myelinated fibers that conduct impulses from mechanical and thermal nociceptors at a great 
speed.  They are responsible for signalling “first pain” (Lamont et al. 2000) which is a sharp 
sensation (Lamont 2008). This type of pain is well-localized and its duration depends on how 
long the acute painful stimulus is activating the nociceptors. On the other hand, if the magnitude 
of the stimulus is sufficient, the C-fiber nociceptors are recruited. They will mediate the “second 
or slow pain” which is a more diffuse and persistent burning sensation than “first pain” and it 
may persist after the acute painful stimulus is over (Lamont et al. 2000). C-fibers are small 
unmyelinated fibers that conduct impulses at a much slower speed and are responsible for 
noxious mechanical, thermal and chemical stimuli (Lemke 2004). These properties contribute 
to the concept of ”second pain”, which is a more diffuse, consuming sensation that is present 
even after the end of the noxious stimuli (Lamont 2008). C-fibers are responsible for most of 
the cutaneous innervation and are also present in muscle and viscera (Lamont 2008). Following 
tissue trauma, changes in the properties of nociceptors occur such that large diameter A-β fibers 
may also become involved in the transmission of pain. There is also a population of “silent” 
nociceptors that may become active during inflammation or tissue damage (Lemke & Creighton 
2010). A-δ and C- fibers are located through the skin, peritoneum, pleura, periosteum, 
subchondral bone, joint capsules, blood vessels, muscles, tendons, fascia and viscera although 
their density may vary depending on species and anatomic location (Lamont et al. 2000).  
The cell bodies of both types of afferent nociceptive fibers discussed before are 
contained in the dorsal root ganglia and their extended axons will synapse with second order 
nociceptive neurons in the dorsal horn of the spinal cord (Lamont et al. 2000, Lemke & 
Creighton 2010). There are different types of nociceptive neurons in the dorsal horn which are 
organized into layers/laminae (Lemke 2004). Primary afferent axons can connect with one of 
three functional populations of dorsal horn neurons (Lamont et al. 2000): (1) interneurons 
which participate in local processing; (2) propriospinal neurons, that are involved in segmental 
reflex activity; and (3) projection neurons, which  participate in rostral transmission since they 
extend axons beyond the spinal cord to terminate in supraspinal centers. This three components 
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are interactive and together facilitate the processing of nociceptive information into an 
organized pain response (Lamont et al. 2000).  
In transverse section, the spinal cord grey matter is divided into 10 laminae according 
to Rexed's classification, based on their light microscopic morphology. The most superficial of 
these is lamina I, and the dorsal horn extends to lamina VI. The ventral horn comprises laminae 
VII-IX, with lamina X being the region surrounding the central canal. Neurons that mediate 
nociception are located primarly in lamina I, lamina II and lamina V (Lemke 2004). The 
projection neurons have also been subclasssified into three groups. The first are nociceptive 
specific neurons (NS), which are concentrated in the superficial laminae of the dorsal horn and 
are excited only by mechanical or thermal noxious input from both A-δ and C- fibers. Wide 
dynamic range (WDR) neurons are the second type of projection neurons and predominate in 
lamina V; WDR can receive input from low-threshold mechanoreceptors as well as nociceptive 
information, including that from A-δ fibers. Although they have a larger receptive field then 
nociceptive specific neurons, their selective activation is still capable of producing pain. The 
third and less known group of dorsal horn neurons are complex neurons which are typically in 
lamina VII and are thought to be involved in the integration of somatic and visceral afferent 
activity (Lamont et al. 2000).  
Afferent nerve fibers and dorsal horn neurons produce and release excitatory and 
inhibitory amino acids and neuropeptides that mediate chemical signalling between various 
neurons within the dorsal horn (Lamont et al. 2000).  
Dorsal horn nociceptive input is conducted to supraspinal centers by projection neurons 
extending through one of the ascending pathways (Lamont et al. 2000). The spinothalamic tract 
is the most prominent nociceptive pathway in the spinal cord and has medial and lateral 
components. It originates from the axons of NS and WDR neurons in laminae I, V, VI, and VII 
which cross the midline and run in the anterolateral white matter (Lamont et al. 2000), 
ultimately projecting to the lateral thalamic nuclei to mediate the sensory aspects of pain 
(Lemke 2004). Pathways contributing to the affective dimension of pain are destined for the 
medial thalamic nuclei and the limbic system via third order neurons - they reflect input from 
larger and more diverse receptive fields (Lamont et al. 2000). The thalamus serves as the relay 
point for sensory information en route to the cerebral cortex (Lamont et al. 2000).  
The spinoreticular tract is formed by axons of nociceptive neurons located more deeply 
in laminae VII and VIII. This pathway ascends anterolaterally in both sides of the spinal cord 
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white matter (Lamont et al. 2000) and projects to the reticular formation in the medulla and 
pons, to thalamic nuclei and then to the somatosensory cortex (Lemke 2004). The reticular 
system is apparently critical to integration of the pain experience, as nociceptive input generates 
a profound effect on reticular neuronal activity. Ascending reticular neurons mediate the 
affective and motivational aspects of pain through their projections to the medial thalamus and 
limbic system while descending reticular activity blocks other sensory activity (Lemke 2004). 
Nociceptive neurons from laminae I and V project through the spinomesencephalic tract to the 
mesencephalic reticular formation and the lateral periaqueductal gray region (Lamont et al. 
2000) – this plays a central role in the integration and modulation of nociceptive input at the 
supraspinal level (Lemke 2004). More recently, another projection transmitting nociceptive 
information from the dorsal horn to the hypothalamus has been discovered - the 
spinohypothalamic tract. It provides an additional route to activate the motivational component 
of pain and initiate neuroendocrine and autonomic responses (Lamont et al. 2000). Because of 
that, it is thought to be responsible for changes in heart rate, arterial blood pressure and 
respiratory rate observed in anesthetized animals during surgical procedures (Lemke 2004). 
Just as dorsal horn processing is vital to the integration of ascending noxious input, its 
role in antinociception is equally crucial. High concentrations of GABA, glycine, serotonin, 
norepinephrine and the endogenous opioid peptides (enkephalins, endorphins, dynorphins) 
have been identified in dorsal horn neurons, and all produce inhibitory effects on nociceptive 
transmission (Lemke 2004).  
Impulse transmission to the cerebral cortex is believed to play a vital role in integrating 
pain perception as it is the seat of conscious experience of pain (Lamont et al. 2000). Imaging 
studies in humans indicate that several discrete regions of cortex are activated by noxious 
stimulation (Lamont et al. 2000). The CNS is capable of modulating the sensation of pain as it 
exerts a “top-down” control modulated by the supraspinal and subcortical cortex, within the 
CNS. This process can explain the influence of attention, anxiety and mood in the perception 
of pain, as well as the fact that a cortical or subcortical lesion can cause severe central pain not 
associated with other pathology. Although there are many species differences regarding 
function and structure, it starts to be clear that the cortex is able to modulate both the cognitive 
and aversive affective aspects of pain sensation and to mediate behaviour patterns (Lamont et 
al. 2000).   
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Descending antinociceptive pathways are able to modulate the pain response. The dorsal 
horn, periaqueductal grey matter of the midbrain, the rostroventral medulla and pons of the 
brain stem and thalamocortical structures are all a part of this system (Lamont 2008). The 
periaqueductal grey matter of the mid brain (PAG) and the rostroventral medulla are thought to 
be the most important pathways. The PAG is viewed as the core for the endogenous analgesia 
system (Lamont 2008) as it receives neuronal input from the cortex, thalamus and 
hypothalamus, and its fibres mainly project to the nucleus raphe magnus in the medulla (Calvey 
& Williams 2009). From the nucleus raphe magnus, the major descending pathways are the 
reticular formation and the reticulospinal tract that will activate inhibitory cells in the substantia 
gelatinosa (Calvey & Williams 2009). In these descending tracts, endogenous opioids and 5-
HT are the main neurotransmitters (Calvey & Williams 2009).  
With the recent collective knowledge of pain processing, its implications for clinical 
practice have been substantial. Rational pain management strategies require an understanding 
of pain physiology – the different types of stimuli, the neural pathways involved in their 
processing, the response of the nervous system to noxious input and the systemic consequences 
(see Figure 4, Appendix I). With all of this anticipation and recognition of pain, the use of drugs 
and other analgesic techniques can be optimized to manage various pain syndromes.   
 
 Clinical Pain 
The model of physiologic pain discussed before has laid the foundation for the 
understanding of nociceptive pathways but it must be recognized that nociceptive pain alone is 
rare in a clinical setting (Lamont et al. 2000). In most situations, the noxious stimulus is 
associated with significant tissue inflammation and nerve injury (Lamont et al. 2000). When 
that happens, dynamic changes in the processing of noxious input are evident in both peripheral 
and central nervous systems and generate clinical or pathological pain. It may be further 
classified into inflammatory pain  when involving somatic or visceral structures or neuropathic 
pain if lesions to the nervous system are present (Lamont et al. 2000). There are different 
features of clinical pain. Causalgia is spontaneous pain that can present itself as dull, burning 
or stabbing. When there is an exaggerated pain response to a noxious stimulus there is 
hyperalgesia. Allodynia happens when there is pain in response to a stimulus that is not 
normally noxious (Lamont et al. 2000).  
In addition, it is useful to characterize clinical pain from a temporal perspective and 
make the distinction between acute and chronic pain. The first one – acute pain – is recent pain 
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that usually arises from soft tissue trauma or inflammation (as in postoperative surgical pain) 
(Lamont et al. 2000). Acute pain also serves a facilitating role as it hypersensitizes the injured 
area (primary hyperalgesia) and the surrounding tissues (secondary hyperalgesia) to other 
stimuli, in this way avoiding external stimuli and assuring a reparative process. Although acute 
pain has its advantages, patients should not be allowed to suffer unnecessarily in the 
postoperative period (Lamont et al. 2000). Chronic pain on the other hand persists beyond the 
duration of a given disease/injury and has a multifactorial nature, being cancer pain, 
osteoarthritic pain and post-amputation phantom limb pain among the most common in 
veterinary practice (Lamont et al. 2000). In dogs, it has recently been described as pain lasting 
longer than one month, associated with a wide range of often subtle behavioural disturbances 
(Wiseman-Orr et al, 2004) and may persist for months or years (Sparkes et al. 2010). In cats, 
chronic pain can be recognised as signs of aggression, decreased appetite and mobility and 
reduced interactions with humans (Sparkes et al. 2010). Unlike acute pain, chronic pain does 
not offer any biological adaptive function and has a great impact on quality of life as it may not 
respond to conventional analgesic treatments (Lamont et al. 2000).  
One of the major characteristics of inflammatory and pathologic pain is that noxious 
stimuli are no longer required for the sensation of pain (Woolf 2010). Therefore, 
hypersensitivity is a basic feature of acute and chronic pathologic pain (Lamont et al. 2000). 
This happens because the nociceptive system is capable of undergoing major changes when 
exposed to inflammatory mediators and growth factors, after injury. Under normal physiologic 
circumstances, mechanical, thermal, and chemical stimuli activate high threshold nociceptors 
associated with A-δ and C- fibers to signal a noxious impulse (Lamont et al. 2000). In the 
clinical setting, however, noxious stimuli are often associated with a degree of tissue 
inflammation – tissue trauma (Lemke 2004). Damaged cells and primary afferent fibers release 
a number of chemical mediators that have direct effects on the excitability of sensory and 
sympathetic fibers and also promote vasodilation with extravasation of plasma proteins and the 
recruitment of inflammatory cells. In addition, mast cells, macrophages, lymphocytes, and 
platelets contribute to the scenario such that inflammatory mediators are produced (Lamont et 
al. 2000). These molecules all act together, generating what is often referred to as a “sensitizing 
soup” that effectively lowers the response threshold for A-δ and C- fiber activation (Lemke 
2004). These changes in the afferent transduction threshold characterize peripheral sensitization 
and are responsible for the zone of primary hyperalgesia surrounding the site of tissue injury. 
In addition to primary hyperalgesia associated with damaged tissue, clinical pain also invokes 
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an enhanced sensitivity in neighbouring areas not subjected to injury (called the zone of 
secondary hyperalgesia) (Lamont et al. 2000).  
It is now recognized that these clinical hypersensitivities are a result of dynamic changes 
in dorsal horn neuron excitability, which modifies their receptive field properties. This will lead 
to peripheral changes as a reduction in the threshold of nociceptor activation at the site of injury, 
and central alteration such as an increased responsiveness of spinal neurons to sensory input 
(Lamont et al. 2000). Central sensitization occurs as an indirect consequence of tissue trauma 
and inflammation and it usually follows peripheral sensitization (Lemke 2004). It represents a 
modification in sensory processing within the central nervous system, such that the threshold 
for generating pain falls and its duration, amplitude and spatial distribution increase (Woolf 
2010). One of the key receptors involved in the alterations underlying central sensitization is 
the NMDA receptor (Lamont 2008) which becomes more responsive to glutamate. In the end, 
central sensitization is characterized by an increase in excitability, expansion in receptive fields 
and an exaggerated response to nociceptive and non-nociceptive stimuli (Lemke 2004). This 
means that innocuous sensations elicited by the low-threshold primary sensory neurons 
discussed above, can become painful through the recruitment of A β fibers as a result of altered 
central processing in the dorsal horn (Lamont 2008). Nociceptor input not only has the capacity 
to produce pain directly, but in producing hyperexcitability in the spinal cord, can produce pain 
indirectly by changing the response to inputs that do not normally produce pain (Lamont et al. 
2000) . 
In summary, the changes occur in nociceptors, whose peripheral terminals become 
sensitized during inflammation, axons become hyperexcitable allowing them to generate 
spontaneous action potentials, synapses in the spinal cord change strength and structure along 
with similar changes in the brain – all of this represents an uncoupling of nociceptive pain from 
its absolute need for noxious stimuli (see Figure 5, Appendix I). Defining the changes in the 
system and when and how they occur, provides a great opportunity for therapeutic intervention. 
(Woolf 2010). 
Pain emanating from visceral structures creates another clinical challenge for veterinary 
practitioners. Unlike skin, which has been the focus of most work on pain physiology, viscera 
are less commonly exposed to external insults but are more commonly the targets of disease 
processes (Lamont et al. 2000) and the protective function of the pain response in this situation 
is not as obvious. 
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Visceral tissue seems to be different when it comes to sensitivity to mechanical, thermal, 
or chemical stimuli. Viscera are apparently most sensitive to distension of hollow muscular-
walled organs (including the gastrointestinal tract, the urinary tract, and the gall bladder), 
ischemia, and inflammation (such as in cystitis or pancreatitis) (Lamont et al. 2000). Visceral 
pain also differs in the way that it is usually perceived as diffuse pain (Lemke & Creighton 
2010) and often associated with nausea and illness  (Lamont et al. 2000).  
 Response to pain 
Although the nervous system is the principal target of nociceptive information and 
allows the organism to react to such input, the pain response involves a much wider network 
apart from the nervous system alone (Lamont et al. 2000). Pain induces reflex responses that 
translate into a catabolic state characterized by hyperglycemia, increased protein catabolism 
and lipolysis, renal retention of water and sodium with increased potassium excretion, and 
decreased glomerular filtration rate (Lamont et al. 2000). Pain often results in a prolonged 
hospital stay, increasing the potential for secondary problems such as immune suppression and 
secondary illness, inappetance, and cachexia (Mathews 2000). In cats, inappetence and 
inadequate caloric intake may lead to hepatic lipidosis during the clinical period (Mathews 
2000). 
These effects constitute the classic "stress response" which may last for days depending 
on the degree of tissue damage. Even though this response is designed to favour survival in the 
post-injury period, it may have an impact on patient debility in a clinical setting. This is why 
attenuation of the pain stress response is an important component of pain management. 
Moreover, the presence of these physiological changes form the basis of most pain assessment 
schemes used in small animals. (Lamont et al. 2000, Mathews 2000). 
3 - Pain Management 
Most clinical pain syndromes are complex (Lamont et al. 2000) and animals are 
presented for surgery with varying degrees of tissue trauma and inflammation (Lemke 2004). 
With that in mind, It should not be surprising that a single protocol, using the same drug at the 
same dose for all the pain syndromes is not an effective as a managing pain strategy in all 
patients (Lamont et al. 2000). If an animal is admitted for elective surgery like a castration, 
there will be no pre-operative trauma and the post-operative trauma and inflammation will be 
minimum – the patient will have a normal physiological pain response that can be managed 
with conventional analgesia therapy like anti-inflammatory drugs or opiods (Lemke 2004). On 
18 
 
the other hand, an animal admitted because of a femoral fracture or for a total ear canal ablation 
will have extensive trauma and inflammation that has been present for days or weeks meaning 
an extensive pathologic response to pain that requires aggressive analgesic therapy (Lemke 
2004). This underlies the importance of practitioners in evaluating the extent of trauma and 
inflammation and, indirectly, the degree of peripheral and central sensitization. This will allow 
a more effective pain management therapy throughout the perioperative period.  
Various strategies of pain management can be arranged with the goal of minimizing 
clinical pain and maintaining physiologic pain at the same time, as a protective and adaptive 
strategy (Lamont et al. 2000). The first of these strategies is preemptive analgesia which 
consists in starting treatment before inducing pain (see Figure 6, Appendix I). This will 
anticipate post-injury hypersensitivity and inhibit peripheral and central sensitization processes 
(Lamont et al. 2000). This concept can be achieved by administering alpha-2 agonists and 
opioids as pre-anaesthetics and by performing local anaesthetic techniques before the surgical 
procedure (Lemke 2004). Multimodal or balanced analgesia is the second strategy and it is 
based on using different classes of analgesic drugs and techniques to achieve additional or 
complementary analgesic effects. This approach permits the use of lower doses and because of 
that, the reduction of potential side effects (Lamont et al. 2000). Clinically, multi-modal 
analgesia consists of choosing drugs that produce sequential blockade of ascending (anti-
inflammatory drugs, local anaesthetics, opioids) and descending (alpha-2 agonists) nociceptive 
pathways (Lemke 2004). Intraoperative use of multimodal analgesic therapy may also improve 
cardiopulmonary function and promote a smoother recovery as it will reduce inhalant 
anaesthetic requirements and autonomic responses to noxious surgical stimuli (Lemke & 
Creighton 2010). A third strategy is mechanism-based therapy – it relies on the theory that 
specific mechanisms can be targeted to manage perioperative pain. In other words, opioids and 
alpha-2 agonists can be used to target nociceptive and anti-nociceptive mechanisms at spinal 
and supra-spinal levels, whilst ketamine works on the NMDA receptor and can prevent central 
sensitization at a spinal level (Lemke 2004). 
Intravenous infusions provide a good option for balanced and effective analgesia in the 
perioperative period. The administration of continuous rate infusions (CRI) and variable rate 
infusions (VRI), depending on the circumstances, has increasingly been used in many 
veterinary practices. Related to these options are the new terminologies like TIVA (total 
intravenous anesthesia) and PIVA (partial intravenous anesthesia). The first notion suggests the 
use of intravenous anaesthetic and analgesic agents for maintenance of anesthesia, excluding 
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the use of volatile agents (Duke 2013). PIVA on the other hand is used to decrease the 
requirements of the inhalant agents (Duke 2013). Although these techniques seem to take more 
importance in the area of anesthesia, a better and more balanced stage of analgesia is achieved 
using this techniques (Duke 2013). With the use of continuous rate infusions, there are no peaks 
associated with the intermittent analgesic use, a more steady level of analgesia is achieved, most 
likely avoiding adverse effects once ideal concentration is determined to each patient. By 
keeping plasma concentrations of a drug steady, receptor occupation and the desired effect will 
be assured (Duke 2013). To achieve that ideal plasma concentration, sometimes an initial bolus 
of the drug is required but that principle does not apply to every drug, take remifentanil for 
example.  
One of the most effective ways to avoid peripheral sensitization and further central 
sensitization is atraumatic tissue handling (Lemke & Creighton 2010). This will decrease the 
level of tissue trauma and inflammation and therefore peripheral sensitization. Regional 
anaesthetic techniques are also effective in the way that they block peripheral nociceptive input 
and prevent central sensitization (Lemke 2004). In fact, local anaesthetics are the only capable 
of achieving peripheral and central neural blockade because they can produce complete 
blockade of peripheral nerve transmission - these techniques are the most effective in 
attenuating sensitization of the central nervous system and avoiding clinical pain (Lemke & 
Creighton 2010). 
Within the next pages, an approach to the different kind of drugs that can be used to 
manage pain will be presented. As I was taught during my stay at the Queen Mother Hospital 
for Animals, there are seven options when it comes to treating pain during a surgical procedure:  
1. Opioids; 
2. NSAIDs; 
3. Alpha-2 agonists; 
4. Local anaesthetics; 
5. NMDA antagonists; 
6. Nitrous Oxide; 
7. Paracetamol.  
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3.1 - Opioids  
 Endorphins, enkephalins, and dynorphins are the endogenous ligands for spinal and 
supraspinal opioid receptors (Lemke & Creighton 2010) and they provide the site of action for 
exogenously administered opioids (Lamont et al. 2000). Opioids have been classified as 
agonists (oxymorphone, hydromorphone, morphine, fentanyl, sufentanil, meperidine 
[pethidine], oxycodone, methadone, and codeine), partial agonists (buprenorphine), or agonist-
antagonists (butorphanol) depending on the dose-response relation of the drug at the various 
opioid receptors (Lamont et al. 2000). Opioids are metabolized in the liver after absorption 
(Kerr 2008). 
There are different opioid receptors which are widely numerous in the periphery 
(including synovial membrane and skin (Kerr 2008), spinal cord and supraspinal structures – 
delta, kappa, mu and the recently discovered orphan receptor (Kerr 2008). The most clinically 
relevant receptors when it comes to analgesia are µ- and κ- receptors (Lamont et al. 2000, 
Greene 2002). Opioid agonists are the most effective class of drugs used for the management 
of perioperative pain in small animals and they are agonists at all 3 receptors – delta, kappa and 
mu (Lemke & Creighton 2010). The µ receptors assist in spinal and supraspinal analgesia and 
sedation (Greene 2002) while κ receptors do not produce supraspinal analgesia since they are 
located primarly in the spinal cord (Kerr 2008). The µ receptor is abundant in somatic tissue 
and its stimulation produces a level of analgesia greater than with any other receptors. This 
analgesia is, as mentioned, accompanied by a level of sedation which might be useful when 
used as premedication in patients (Beckman 2013). 
 The full µ agonists (with morphine, methadone and hydromorphone  the most 
commonly used in small animals) are recommended for severe to moderate pain as they achieve 
a maximum effect (Beckman 2013). Besides, their use reduces the inhalant agent requirements 
by 50% (Lemke & Creighton 2010). Following the same logic, partial agonists (buprenorphine) 
are useful in the treatment of moderate to mild pain, and agonists-antagonists don’t have an 
appreciable effect on the µ receptor (Beckman 2013).  
Opioids raise the pain threshold or decrease the perception of pain by acting at receptors 
in the dorsal horn of the spinal cord and mesolimbic system (Greene 2002). In the dorsal horn, 
opioid receptor activation can cause pre- and post-synaptic effects, inhibiting nociceptive 
transmission and ascending nociceptive pathways, respectively (Lamont 2008).  Centrally, at 
the level of the mesencephalon and medulla, opioids activate the descending endogenous 
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antinociceptive system that modulates nociception in the dorsal horn via release of serotonin 
(Greene 2002). They act at the limbic system to alter the emotional component of pain response, 
modifying its perception (Lamont 2008) thus making it more bearable (Greene 2002).  
 As opioids reduce peripheral and central afferent nociceptive transmission, they are 
effective in treating acute inflammatory pain. However, neuropathic pain syndromes respond 
poorly to these drugs (Lamont et al. 2000). Although dosing should be taken into account when 
using pure agonist opioids, they do not have “ceiling” effect which means they can be given to 
the patient to effect (Mathews 2000). On the other hand, when using opioid partial agonists or 
agonist-antagonists, one should take into account that they do have that ceiling effect and 
because of that, adherence to maximum dose is important with these this drugs (Mathews 2000).  
Opioids can be administered via many routes including (1) systemic administration-
orally, subcutaneously, intramuscularly, or intravenously (as a bolus or a constant-rate 
infusion), (2) epidural or spinal injection, (3) transdermal application, (4) intra-articular and (5) 
local administration at the site of injury (Lamont et al. 2000). The most commonly used opioids 
in infusions are morphine, hydromorphone, fentanyl, sufentanil, and remifentanil (Duke 2013). 
One should take into account the reflex bradycardia from the increase in vagal tone and 
respiratory depression effects (Duke 2013), depression of cough centers and induction of 
bronchospasm secondary to histamine release and decreased cerebral blood flow and 
intracranial pressure (Greene 2002). 
Morphine is one of the first ever studied opioids and because of that all the opioids are 
compared to morphine in potency. It is a pure agonist at μ receptors, although it has some 
affinity for κ and δ receptors (Kerr 2008). Morphine given intravenously rapidly may cause 
hypotension (because of histamine release) as well as excitement and vomiting (Mathews 2000) 
and histamine release (Greene 2002) and profound vasodilation (Quandt 2013). The same 
happens with pethidine, whose intravenous administration is contraindicated given its mast cell 
degranulation, histamine release and decrease in systemic arterial blood pressure (Kerr 2008). 
Morphine can be given slowly over 5 minutes to avoid these side effects (Mathews 2000). After 
parenteral administration, morphine lasts between 2 to 6 hours (Kerr 2008) and when given 
epidurally it may last up to 24h but the onset of action takes approximately 1 hour (Lemke & 
Creighton 2010). It can be administered as a CRI for prolonged analgesia (Kerr 2008), avoiding 
the side effects associated with repeated bolus. The use of morphine as an analgesic is more 
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valuable in cases of continuous, poorly localized pain from visceral and deep structures, it is 
not as effective in pain arising from superficial structures (Calvey & Williams 2009).  
Pethidine is a semi-synthetic μ-agonist and its potency is only one-third to one-fifth that 
of morphine (Kerr 2008) The duration of action is between 1 to 2 hours (Kerr 2008) in dogs 
and cats and it is recommended in the management of mild pain. It has low emetic effect and 
produces light sedation.  
Fentanyl is a 100 times more potent than morphine and it may reduce the inhalation 
anaesthetic requirements by up to 50%, improving cardiovascular function (Lemke & 
Creighton 2010). It can be administered intramuscularly, subcutaneously, intravenously and 
transdermally. Fentanyl’s duration of action is approximately 20 to 30 minutes (Mathews 2000) 
and has an onset of action of 1 to 2 minutes (Kerr 2008), permitting a more accurate titration of 
dose without compromising the patient’s long term status. A transdermal fentanyl patch is a 
delivery system for continuous administration of an analgesic in dogs and cats. This route of 
administration has some advantages over parenteral administration: non-invasive dosing, 
avoids the gastro-intestinal tract, lack of first-pass metabolism and continuous drug delivery 
(Linton et al. 2012). Fentanyl patches require advance application to be effective for 
perioperative pain management (Mathews 2000). The recommended location for placement is 
the dorsal or lateral thorax, the area should be clipped and washed with soap and it must be dry 
before application (Kerr 2008). It should be held against the skin after applying for at least 60 
seconds. There is individual variation in reaching therapeutic plasma drug concentrations after 
patch application in cats (6-12 or more hours) and dogs (12-24 or more hours) (Mathews 2000) 
but if they stay adherent to the patient’s skin, its effect may last between 3 to 5 days (Lemke & 
Creighton 2010) but after 72h the plasma concentration starts to drop and it should be removed 
(Kerr 2008). Recently, a transdermal fentanyl solution - Recuvyra™, from Elanco Companion 
Animal Health - became licensed for dogs for the management of post-operative pain in 
orthopaedic and soft tissue surgery. It can provide four days of pain control when applied two 
to four hours prior to surgery between the shoulder blades. In fact, if a transdermal fentanyl 
solution is applied topically 2-4h prior to an orthopaedic or soft tissue surgery, effective levels 
of analgesia are maintained for 4 days (Linton et al. 2012). Some animals never achieve 
effective drug concentrations (Mathews 2000) and it may not be possible to guarantee 
achievement of good analgesic levels at the time of surgery when used pre-operatively. 
Transdermal absorption of fentanyl may be compromised by altered body temperature, in 
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surgical patients (Lemke & Creighton 2010). Adjunct analgesia is required until effective 
analgesia is reached (Mathews 2000).  
Sufentanil, alfentanil and remifentanil are all derivatives of fentanyl with a short term 
action (Kerr 2008). Remifentanil is metabolized by plasma esterases (Duke 2013) and that 
makes it unique in the way that it is rapidly eliminated after infusion, resulting in a short 
duration of action that can be very useful in certain cases. For that reason, it is usually used as 
an infusion to provide additional analgesia during anesthesia (Kerr 2008).  
Buprenorphine has an onset of action of 45 minutes and a reported duration of action of 
6 hours (Mathews 2000). Although it is not a pure μ-agonist, buprenorphine has a high receptor 
affinity and can even remove morphine from the receptor (Kerr 2008).  
Butorphanol is an agonist at the ĸ receptor and an antagonist or partial agonist at the µ 
receptor (Warne et al. 2013). Given these properties, butorphanol can be used to reverse the 
effects of a pure μ-agonist and it should not be used in combination with them (Kerr 2008). It 
is considered adequate for moderate visceral pain management but has poor effect on somatic 
analgesia (Warne et al. 2013) and for post-operative analgesia in minor surgical procedures. 
For butorphanol, the duration of effect is short (2 hours) which may require repeat 
administration or the use of a CRI (Mathews 2000).  However, common side effects from the 
use of other opioids (morphine, hydromorphone, or fentanyl) such as vomiting, respiratory 
depression and bradycardia are less likely to occur after administration of butorphanol (Lemke 
& Creighton 2010). Although it is not recommended in cases of severe pain, butorphanol is the 
preferred analgesic in a vomiting patient for its anti-emetic properties (Quandt 2013). In 
addition, it also reduces isoflurane requirements up to 20% in dogs and cats (Lemke & 
Creighton 2010).  
Methadone is a widely used synthetic pure μ- receptor agonist in veterinary medicine. 
Methadone is highly protein bound, has a slow onset of action but a long duration (Calvey & 
Williams 2009). It is 10 to 50 times more potent than morphine and causes less sedation (Kerr 
2008), and its use is indicated in cases of severe pain (Warne et al. 2013). Unlike morphine, 
methadone has poor emetic effects but causes more dysphoria (Kerr 2008). Apart from this, 
methadone also has some influence on the NMDA receptors, mediating additional analgesia 
(Warne et al. 2013). Methadone has a duration of action of approximately 4 hours.  
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Tramadol is an atypical opioid analgesic (Kerr 2008), which has high agonist activity at 
µ receptors and some affinity at  the κ and δ receptors (Calvey & Williams 2009). Besides this 
effect, tramadol also inhibits serotonin and noradrenaline, reducing nociceptive transmission in 
the spinal cord (Kerr 2008) to the brain through indirect activation of descending pathways 
(Calvey & Williams 2009). It can be used in the management of post-operative pain and in 
acute, severe perioperative pain (Lamont 2008) . Animals may show sedation and dysphoria 
after the use of tramadol (Lamont 2008) but when compared to other opioids it is less likely to 
cause respiratory depression (Calvey & Williams 2009).  
Many injectables (thiopental, propofol) do not alter nociceptive processing, but simply 
cause unconsciousness (Lemke 2004). This means the animal will feel pain but can’t react to it 
and because of that their use is not effective in pain management therapy.  
Respiratory depression induced by opioids is a fairly common side effect (Beckman 
2013). Bradycardia responsive to anticholinergics, secondary to increased vagal tone is usual 
after the use of pure μ-agonists (Kerr 2008). Also, hypothermia seems to be an undesirable 
effect observed in dogs, while hyperthermia may be more common in cats (Beckman 2013). 
With some μ-agonists (like morphine), defecation and vomiting may be present (Beckman 
2013). In ophthalmologic surgery, it should be taken into account that μ-agonists produce 
miosis in dogs and mydriasis in cats (Kerr 2008). In general, the geriatric or young patient and 
those patients with liver or renal disease should receive special consideration with regard to 
specific drugs and their dosage - hepatic or renal compromise may lead to a prolonged effect 
rather than an overdose (Mathews 2000). In case of an overdose, naloxone, a reversal agent, 
can also be administered to remove the unwanted adverse effects, preserving the analgesia 
(Mathews 2000) if small doses are carefully used. Although it is not always clear, μ-opioid 
receptors typically cause euphoria and kappa-agonists produce dysphoria (Kerr 2008). These 
effects can be controlled with the use of sedatives and/or opioid antagonists.  
3.2 - Local anesthetics  
The principle effect of local anesthetics in the nociceptive pathway is inhibition of nerve 
impulse conduction along Aδ and C fibers and because of that blocking the transmission of 
nociceptive signals to the central nervous system (Lamont 2008).By blocking sodium channels 
in nerve fibers, local anaesthetics block the generation and conduction of nerve impulses 
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(Lemke & Creighton 2010) and nociceptor excitation (Lamont et al. 2000). When administered 
centrally they can inhibit modulatory nociceptive processing (Lamont et al. 2000).  
Lidocaine has a fast onset of action – about 10 minutes - and a duration of action of 1-
2 hours as well. It is mostly used for short diagnostic and surgical procedures (Lemke & 
Creighton 2010). Mepivacaine has a longer duration of action (about 2 to 3 hours). In 
comparison, bupivacaine is 4 times more potent than lidocaine with an onset of action of 20 
minutes and duration up to 6 hours (Lemke & Creighton 2010), being used during surgical 
procedures. Ropivacaine takes 10 to 20 minutes to act and has a duration of action between 3 
to 5 hours, it is 3 times more potent than lidocaine.  
Techniques like regional and local nerve blocks and epidural analgesia are important 
components in preventing and managing pain and should be explored by clinicians as a part of 
an effective multimodal management plan (Lamont 2008). Epidural analgesia is frequently used 
to prevent, reduce, or treat pain in dogs and cats - it provides intraoperative analgesia and 
reduces anaesthetic requirements (Mathews 2000).  
Clinicians should always keep in mind the good use of peripheral or central neural 
blockade during surgical procedures as a part of their pain management strategy – it will reduce 
inhalation agent requirements, decrease the response to trauma and improve recovery (Lemke 
& Creighton 2010). Systemic use of lidocaine in the perioperative period is also an option and 
it decreases inhalation agent requirements, controls ventricular arrhythmias, prevents post-
operative ileus and provides analgesia (Lemke & Creighton 2010).  
3.3 - Nonsteroidal anti-inflammatory drugs  
NSAIDs are a widely used group of drugs used in veterinary medicine for their 
analgesic, anti-inflammatory and anti-pyretic effects (Monteiro‐Steagall et al. 2013). It is 
believed that the analgesic effects of NSAIDs are related to their ability to inhibit 
cyclooxygenase (COX) activity and prevent peripheral nociceptor sensitization (Lamont et al. 
2000) by preventing the formation of prostaglandins (Beckman 2013). Production of 
prostaglandins in the dorsal horn of the spinal cord also contributes to the development of 
central sensitization (Lemke & Creighton 2010). Prostaglandins do not directly cause pain but 
they sensitize C fibers to nociceptive peptides (Calvey & Williams 2009). As prostaglandins 
are involved in perpetuating inflammation and sensitizing neurons to stimuli, NSAIDS are 
effective agents in the management of pain associated with inflammation (Beckman 2013). 
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Prostaglandins also play a part in vascular homeostasis, gastroprotection, renal function and 
blood flow, blood clotting, reproduction, bone metabolism, wound healing, nerve development 
and growth, and immune responses (Sparkes et al. 2010). Inhibition of both COX-1 and COX-
2 will stop conversion of arachidonic acid to prostaglandins and thromboxanes (both involved 
in tissue inflammation), producing an anti-inflammatory effect (Lemke & Creighton 2010). 
They also inhibit the production of leukotrienes through the lipoxygenase enzymes (Sparkes et 
al. 2010). Because of these properties, this class of drugs has efficacy in the inhibition of 
peripheral sensitization and is indicated in acute perioperative pain and some chronic pain 
syndromes (Lamont 2008). At the level of the dorsal horn, inhibition of cyclooxygenase will 
achieve a central analgesic effect (Lamont 2008, Lemke & Creighton 2010). NSAIDs undergo 
hepatic metabolism and the metabolites are excreted in the kidney (Kerr 2008). In comparision 
with opioids, NSAIDs  do not have cardiovascular, respiratory or behavioural effects, but have 
anti-inflammatory properties and are available for oral administration(Kerr 2008). 
There are many available NSAIDs available for the use of perioperative pain in dogs - 
aspirin, carprofen, cinchophen, deracoxib, etodolac, firocoxib, flunixin, ketoprofen, 
meloxicam, phenylbutazone, tepoxalin, tolfenamic acid and vedaprofen (Lascelles et al. 2007) 
but the licensed ones in dogs only include carprofen, meloxicam, ketoprofen, tolfenamic acid, 
firocoxib and tepoxalin(Kerr 2008). However, the list of approved NSAIDs in cats is much 
shorter – carprofen, ketoprofen, aspirin, meloxicam, tolfenamic acid and robenacoxib, 
depending on each country (Sparkes et al. 2010). For long term use, only meloxicam and 
robenacoxib are approved (Sparkes et al. 2010). The use of NSAIDs is avoided in cats because 
they are not capable of a good hepatic glucuronidation and that is the major mechanism of 
metabolism and excretion of this group of drugs (Lascelles et al. 2007) .  
NSAIDs are usually administered systemically - orally, subcutaneously, 
intramuscularly, or intravenously. Recently local administration has gained some importance 
as it helps to maximize drug levels at the site of inflammation while minimizing overall 
systemic tissue exposure and the potential side effects (Lamont et al. 2000) . NSAIDs can be 
given alone postoperatively or in combination with opioids (Lemke & Creighton 2010).  
Ketoprofen is a non-specific COX inhibitor with an onset of half an hour and duration 
of action of 12 hours (Lemke & Creighton 2010). It is approved for chronic pain administration 
and post-operative analgesia in dogs (Kerr 2008). Because of its non-specific properties, 
ketoprofen has an effect on platelet aggregation and gastrointestinal ulceration (Kerr 2008).  
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Carprofen is a selective COX-2 NSAID and it has a slower onset when compared to 
ketoprofen – 1-2- hours (Lemke & Creighton 2010). Its efficacy is comparable to pethidine 
(Kerr 2008), only with a longer duration of action (12-18 hours). Its use is effective in providing 
post-operative analgesia and in the treatment of long term conditions in dogs.  Carprofen does 
not inhibit formation of thromboxane and gastrointestinal effects from long-time 
administration, although it is associated with some level of hepatotoxicity (Kerr 2008). 
Meloxicam is also a COX-2 selective inhibitor. It has been used to achieve post-
operative analgesia in dogs and cats and to treat long-term conditions in dogs (Kerr 2008). It 
has a reported duration of 24 hours, with an onset similar to carprofen (Lemke & Creighton 
2010).  
Tolfenamic acid is another COX-2 inhibitor, it is also recommended for post-operative 
and chronic pain management in cats and dogs (Kerr 2008). It has good anti-pyretic and anti-
inflammatory properties but it is capable of some decrease in thromboxane formation (Kerr 
2008).  
Firocoxib and tepoxalin are recently released NSAIDs and their efficacy needs further 
studying but they are both available for treatment of ostheoarthritis in dogs (Kerr 2008). 
Paracetamol has good analgesic and antipyretic properties but its anti-inflammatory 
effect is poor. Paracetamol is used in the treatment of moderate pain and it doesn’t have gastric 
irritation or bleeding effects (Calvey & Williams 2009) .   
Side effects related to the use of COX inhibitors are not usually a problem in healthy 
animals with normal platelet, gastrointestinal, and renal function (Lemke & Creighton 2010). 
Because of that, NSAIDs should be avoided until the renal, hepatic, circulatory, and coagulation 
status of the patient is known and the lowest dose to alleviate pain should be given, reducing 
the potential of adverse effects (Mathews 2000). Gastric ulcers can be prevented with the use 
of misoprostol (synthetic prostaglandin E) and sucralfate (Kerr 2008). There is not a great 
benefit in pre-operative use of NSAIDs (Lemke & Creighton 2010) but carprofen and 
meloxicam have been assessed and found to be safe in healthy dogs when given in advance of 
anesthesia.  
3.4 - Αlpha-2 adrenergic agonists  
Alpha-2 receptors in the dorsal horn of the spinal cord inhibit release of nociceptive 
neurotransmitters (Greene 2002), They modulate the release of substance P, calcitonin gene-
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related peptide, and various other neurotransmitters involved in rostral transmission of 
nociceptive information (Lamont et al. 2000). Norepinephrine is the endogenous ligand for 
spinal and supraspinal alpha-2 receptors (Lemke & Creighton 2010). Alpha-2 receptors are 
linked to membrane-associated G proteins that induce a chain of events that open potassium 
channels in the neuronal membrane (Greene 2002). Loss of intracellular potassium 
hyperpolarizes ascending neurons, making them less responsive to excitatory input and 
inhibiting the passage of painful stimuli through the CNS (Greene 2002) . Alpha-2 receptors 
are also located supraspinally in the locus ceruleus, thalamus, and cerebral cortex and when 
activated, may cause profound sedation which decreases the perception of pain (by inhibiting 
norepinephrine release) (Lamont et al. 2000) and activate the descending antinociceptive 
pathways (through projections in the locus ceruleus) (Lamont 2008). In addition, the receptors 
in the locus ceruleus mediate sedation and muscle relaxation (Lamont et al. 2000) . In general, 
alpha-2 agonists can provide dose-dependent sedation, muscle relaxation and anxiolysis 
(Greene 2002, Beckman 2013) as well as analgesia in very painful animals as they decrease 
norepinephrine release, both peripherally and centrally, and reduce nociceptive transmission 
(Quandt 2013). 
Alpha-2 agonists can be administered systemically, epidurally or peripherally to prolong 
sensory nerve blockade achieved by local anaesthetics since they are capable of some C-fiber 
conduction blockade, even if there are no receptors in the axons of peripheral nerves (Lamont 
et al. 2000).  
Alpha-2 agonists can be combined with opioids and dissociative agents for further 
analgesia effects (Quandt 2013). This group of drugs can be used in combination with opioids 
as they produce analgesic effects through similar modulatory pathways (Lamont 2008). This 
co-administration may result in synergistic drug interactions and the use of alpha-2 agonists 
may be useful when opioids are no longer an option (Lamont et al. 2000). Alpha-2 agonists 
may be applied perineurally with a local anaesthetic to improve the intensity and duration of 
the blockade, as they are capable of decreasing the conduction of the impulse (Lamont 2008). 
The alpha-2 agonists are effective for pre-emptive analgesic use and selected cases of 
pain management in the young healthy patient (Mathews 2000). They may cause arrhythmias - 
bradycardia, first and second degree atrioventricular blocks, sinus arrest and decreased cardiac 
output (Greene 2002).  
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Whether given IV or IM, alpha-2 agonists typically cause an acute increase in vascular 
resistance  and blood pressure (Kerr 2008). This is associated with activation of the receptors 
located in several large vascular beds – skin, mucous membranes and GI tract. The typical 
response to this acute increase in pressure is the development of reflex vagal bradycardia 
(Greene 2002). After a while, the central action of α-2 agonists begins to take effect, causing a 
decrease in sympathetic neuronal terminal release of norepinephrine which will reduce baseline 
vascular tone and possibly in a reduction of blood pressure (Greene 2002). All alpha-2 agonists 
reflexly decrease heart rate in response to the rapid increased vagal tone (Kerr 2008). Dogs and 
cats with suspected or potential cardiopulmonary dysfunction should not be given this agent 
because they will rapidly increase afterload. In dogs with dilated cardiomyopathy and weakened 
systolic function these agents should never be given, nor in dogs with mitral valve disease 
(Greene 2002). If the bradycardia becomes clinically relevant, atipamezole can be administered 
as a reversal agent (Quandt 2013). Anticholinergics are not recommended in treating 
bradycardia induced by the use of these agents (Quandt 2013) because the increased heart rate 
can dramatically increase blood pressure.  
Medetomidine and dexmedetomidine are two of the most used alpha-2 agonists. 
Medetomidine is a mixture of 2 enantiomers whereas dexmedetomidine is the active enantiomer 
(Lemke & Creighton 2010) and it achieves its effects through the alpha-2 adrenergic receptors 
in the dorsal horn of the spinal cord. For this reason, dexmedetomidine is twice as potent as 
medetomidine (Lemke & Creighton 2010) as well as more expensive. It can be used as a 
constant rate infusion and in combination with ketamine, the reflex bradycardia in response of 
hypertension can be controlled (Quandt 2013) . Dexmedetomidine is not recommended in 
animals with urinary obstruction or diabetes mellitus as it may induce polyuria and 
hyperglycemia (Quandt 2013). Medetomidine has a rapid onset of action and duration of 
approximately 1 hour in dogs (Lemke & Creighton 2010). It may be combined with opioids or 
local anesthetics when performing epidurals but medetomidine is very lipophilic which means 
it will clear from the epidural space quickly because it is absorbed systemically (Lamont 2008).  
3.5 - NMDA antagonists 
The NMDA receptor is activated by glutamate – the endogenous agonist for spinal and 
supraspinal NMDA receptors (Lemke & Creighton 2010). NMDA receptor activation induces 
a number of second message systems – increased neuronal hyperexcitability, decreased 
thereshold and expansion of receptive fields of noci-responsive neurons within the dorsal horn 
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of the spinal cord (Greene 2002). As such, the origin of pain is from the central nervous system 
itself - central hypersensitisation (Greene 2002).  
Dissociative agents like ketamine and tiletamine interrupt the ascending transmission 
from the unconscious to the conscious part of the brain via depression of the thalamo-cortical 
region (Greene 2002). These agents decrease cardiovascular function but increase sympathetic 
tone, which results in overall stimulation of cardiovascular function: increased cardiac output, 
tachycardia (Greene 2002) and increased arterial blood pressure (Quandt 2013).  
Although there are multiple binding sites, it is the NMDA receptor blockade that 
accounts for most of the analgesic effects of ketamine (Lamont et al. 2000).  Ketamine is the 
most widely use agent in this class of drugs for its analgesic properties (Lemke & Creighton 
2010). Ketamine can prevent, and, in some cases, reverse the development of central 
sensitization (Lemke 2004) given the importance of the NMDA receptor in that process 
(Lamont 2008) . It may even abolish hypersensitivity, therefore, the spinal cord modulatory 
effects of ketamine make it particularly useful in the management of chronic neuropathic types 
of pain that typically respond poorly to opioid treatment (Lamont et al. 2000). Analgesic effects 
of ketamine may be achieved by systemic administration (intramuscularly or intravenously as 
a bolus or constant-rate infusion), epidural administration, or topical application to burn injuries 
(Lamont et al. 2000). Since ketamine antagonizes the NMDA receptor in  small doses, it can 
be administered as a component of a CRI (Beckman 2013). Ketamine may be used for peracute 
pain management as an adjunct to other analgesics or sedative options, or when short-term 
analgesia is required and opioids are not available or are inadequate (Mathews 2000). Ketamine 
infusion provides good analgesia in cases of chronically painful patients and patients with great 
level of central sensitization (Duke 2013). However, in cases of sustained traumatic brain 
injury, ketamine is not recommended as it can increase both intracranial pressure and 
intraocular pressure (Quandt 2013). In patients undergoing major procedures that involve 
surgical trauma, ketamine and opioid infusions intra- or post-operatively can be beneficial for 
the animal (Lemke & Creighton 2010) . Side-effects that may arise from the use of ketamine 
infusions are increased systemic blood pressure and body temperature, mydriasis, regurgitation, 
cardiac arrhythmias, and dysphoria in conscious patients (Duke 2013). Seizures may occur after 
high doses of ketamine (Lemke & Creighton 2010). Besides, its use is associated with muscle 
rigidity, and can be combined with a benzodiazepine or an alpha-2 agonist for muscle relaxation 
(Quandt 2013). 
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3.6 - Inhalant analgesics 
 Nitrous oxide is an inhalant gas that has been used for its analgesic properties in 
combination with other anaesthetic inhalants. In the past, it was commonly known as “laughing 
gas”. Nitrous oxide is very insoluble and when used with other inhalant agents like halothane, 
it can increase anaesthetic uptake of the second agent – the so-called “second gas 
effect”(Mathews 2008). When using nitrous oxide, it is imperative that the oxygen inspired 
concentration is at least 33% and after surgery, a good level of oxygenation should be provided 
because the nitrous oxide leaves the blood very quickly and there is a risk of diffusion hypoxia 
(Mathews 2008). It causes mild sympathetic stimulation (supporting the cardiovascular 
system). The mechanism of its analgesic effects is not certain but it is thought to act on opioid 
receptors in the periaqueductal grey matter, which projects to the dorsal horn of the spinal cord 
to act on the alpha-2 receptors (Calvey & Williams 2009). Besides, this gas is also capable of 
antagonizing glutamate at NMDA receptors (Calvey & Williams 2009). 
III - Intra-operative analgesia in the anesthetized animal 
 In the next paragraphs, different options of providing analgesia in the anesthetized 
animal during surgical procedures will be presented. It is important to remember how to 
recognize pain in an anesthetized animal in a surgical scenario – it is usually shown as an 
increase in heart rate, respiratory rate and/or blood pressure which may or may not be related 
to a direct surgical stimulus. In the post-operative period there are many available pain 
assessment scales that can be of use in that matter. Since pain syndromes vary depending on 
different types of surgical trauma, it seems logical to divide forms of analgesia according to 
type of surgery. It is important to keep in mind the available options to provide analgesia:  
 Opioids; 
 Alpha-2 agonists; 
 Non-steroidal anti-inflammatory drugs; 
 N-methyl D-aspartate receptor antagonists; 
 Local anaesthetics; 
 Nitrous oxide; 
 Paracetamol.  
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These alternatives were chosen taking into account the choices made by the anaesthetists 
during the time spent with the Anaesthesia and Analgesia Service at the Queen Mother Hospital 
for Animals.  
1 - Orthopaedic surgery 
In most cases, orthopaedic surgery is associated with constant, long-lasting, strong pain and 
a great level of manipulation. A good option for intraoperative analgesia is setting up a ketamine 
CRI. Ketamine works very well in the relief of chronic pain and is capable of preventing central 
sensitization - it can inhibit ascending transmission from the unconscious to the conscious part 
of the brain and reduce the activity of neurons in the spinal cord. It is important to start with a 
bolus of ketamine to achieve effective plasma concentrations rapidly. Another option is 
combining a ketamine CRI with opioids: intermittent top-ups of methadone, or a fentanyl CRI. 
When opioids or ketamine are not available or can’t be used in a specific case, local anaesthetics 
and alpha-2 agonists must be considered. A lidocaine CRI is capable of reducing intraoperative 
pain and it decreases inhalation agent requirements, and is normally used when the use of 
opioids are restricted or contra-indicated. Medetomidine and alpha-2 agonists in general are 
mostly used for post-operative pain management but they are always an option. In orthopaedic 
and neurosurgery, ketamine is the drug of choice. Although opioids are capable of achieving 
good analgesia, a multimodal approach is always good practice and usually more effective.  
Epidurals and peripheral nerve blocks are a very useful strategy in orthopaedic surgeries 
when managing pain. Local and regional anaesthetic techniques apply in dental surgery 
(maxillary and inferior alveolar nerves), forelimb (brachial plexus) and hind limb (lumbar 
nerves using epidural administration), thoracic procedures (intercostal nerves), among others. 
They do not fall into the category of intraoperative analgesics as they are performed before 
surgery but it is important to be reminded of their effect on pain control and animal comfort 
during surgery. Local anaesthetics are injected close to the nerves and will penetrate the 
peripheral nerves to block the generation and conduction of nerve impulses. By preventing 
transmission of noxious stimuli to the spinal cord, they will prevent central sensitization. These 
techniques are usually performed after induction and at least 10 to 20 minutes before the 
surgical procedure to allow time for the onset of action. A good knowledge of anatomical 
landmarks and location of nerves is essential to perform an effective local or regional block 
technique.  
2 - Soft Tissue Surgery 
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There are a number of procedures and types of surgery that fall into this category, being 
gastrointestinal, urinary tract, hepatic, cutaneous, ear and reproductive surgery some of the most 
common. Opioids are the most commonly used group of drugs and they can be used as constant 
rate infusions - with fentanyl, remifentanil, morphine, and methadone – or as intermittent 
intravenous administrations mainly using methadone. Opioids decrease the propagation of 
action potentials and mu agonists mediate supraspinal and central analgesia. Other opioids like 
buprenorphine are mostly used if surgery is associated with mild to moderate pain. The use of 
ketamine as a CRI is an effective option especially in cases where chronic pain is present and 
there is a risk of hyperalgesia (as in a total ear canal ablation with chronic ear disease). Nitrous 
oxide as an analgesic agent can be useful in visceral pain management when opioids and 
ketamine are being used and there are few other options. Paracetamol is also used in some types 
of soft tissue procedures, most of the time as a last resource when all other options were 
exhausted.  
Hepatic surgery: although hepatic procedures are a part of soft tissue surgery, there are some 
peculiarities, especially the fact that many analgesics are metabolized in the liver. 
Medetomidine should be avoided in liver and heart conditions given its cardiovascular side 
effects and need for hepatic metabolism. Ketamine is not a good option either because it is also 
metabolized in the liver and is highly protein bound. Opioids are the first option in liver surgery. 
Taking that into consideration, a fentanyl constant rate infusion can be used to provide analgesia 
during hepatic interventions. It should be preceded by a fentanyl bolus to achieve effective 
plasma concentrations. The best option is maybe remifentanil since it is not metabolized by the 
liver at all and has a rapid elimination rate after the infusion stops. An epidural with morphine 
is capable of achieving satisfactory analgesia if we use enough volume. Another option would 
be opioid administrations such as methadone every 4 hours.  
3 - Thoracic surgery 
Thoracic procedures sometimes involve a great amount of generated pain. Once again, 
nerve blocks can play a major role in this type of surgery. Intercostal and sternal blocks should 
always be taken into consideration in the pain management plan. Once again, a morphine 
epidural is a very good strategy for thoracotomies as it can produce spinal analgesia. The main 
particular aspect about thoracic surgery is that positive-pressure ventilation may be necessary 
but analgesics don’t interfere with that. Because of that, the analgesic principles of thoracic 
surgery follow the same rules as soft tissue surgery which means continuous rate infusions of 
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fentanyl and ketamine can be used, with a bolus first, and intermittent methadone intravenous 
injections are another resource. Nitrous oxide should probably be avoided in cases of 
pneumothorax because it can diffuse from the blood into gas pockets.  
IV - Practical Cases 
1 - Bella 
Bella is the cutest female Dachshund who came in for an extrahepatic porto-systemic shunt 
correction (see Figure 7, Appendix I). She was premedicated with Methadone 0,1 mg/kg IV 
and induced with Propofol 4 mg/kg IV. Bella only had 0,1 mg/kg as premedication because of 
the liver. Acepromazine was not used in the premedication also because it requires hepatic 
metabolism and therefore may have a prolonged duration of action in these cases. An epidural 
with preservative-free morphine 0,1 mg/kg was performed using the loss of resistance 
technique. A remifentanil CRI was set up during surgery because it does not rely on hepatic 
metabolism (see Figure 8, Appendix I).  
The main considerations in porto-systemic shunt surgeries are: 1) low plasma protein 
concentrations (especially albumin) – the anaesthetist should be careful with highly protein 
bound drugs; 2) drug metabolism - hepatic or extrahepatic; 4) hypoglycemia; 5) pain; and 6) 
bleeding. For post-operative analgesia, we should keep in mind that the epidural with morphine 
would produce good analgesia for up to 24 hours. In addition, Bella had 0,2 mg/kg IV after 
surgery (she only had 0,1 mg/kg in premedication) which will be repeated every 4 hours, 
depending on regular pain assessments.  
2 - Truffle 
Truffle is a 4 year-old female Bloodhound who came for a Total Ear Canal Ablation because 
she had a bilateral otitis externa and media with perforated tympanic membranes. In the 
premedication we used acepromazine (0,005 mg/kg) and methadone (0,2 mg/kg), for induction 
we used propofol (4 mg/kg). Chronic otitis externa is a very painful condition, the methadone 
used in premedication will provide a good level of pain control through supraspinal analgesia.  
We performed a bilateral auriculo-temporal and great auricular nerve block using 1 mg/kg 
of ropivacaine. The block will on the auricular cartilage and external ear canal but does not 
provide analgesia of the bulla. Ropivacaine will provide analgesia during the surgical procedure 
and sometime after since its effect lasts between 3 to 5 hours. This local anaesthetic will 
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penetrate the connective tissue of the nerve fibers and inhibit voltage-gated sodium channels in 
neuronal membranes therefore blocking generation and conduction of the nerve impulses.  
Both ears were very painful so further doses of methadone were ready to administer if 
required. A ketamine CRI was also administered at a dose of 10 μg/kg/min, preceded by a bolus 
loading dose of 0.5 mg/kg. In this case it is very good to use ketamine because the animal has 
chronic pain and ketamine is very effective in treating hyperalgesia. Ketamine will reduce 
neuron activity in the spinal cord in response to nociceptive stimuli and reduce sensitivity of 
these neurons by inhibiting NMDA receptors.  
If we needed any other type of analgesia, we could use alpha-2 agonists and nitrous oxide 
since we had already performed nerve blocks will local anesthetic, and were administering 
opioids and NMDA antagonists. We decided to use nitrous oxide, which in a rebreathing system 
should be administered in a 1:1 ratio with oxygen. When starting the nitrous oxide, we recorded 
the inspired fraction of oxygen to make sure that the animal did not receive a hypoxic gas 
mixture. The inspired fraction of oxygen should not be less than 33%. Nitrous oxide acts 
centrally, like ketamine. We gave methadone during the surgery when heart rate and blood 
pressure increased and she had the last dose before going to recovery. In the post-operative 
period, Truffle is going to have 0,1-0,2 mg/kg Methadone IV depending on the pain evaluation 
scale.  
3 - Arthur 
Arthur is an 11-month year old Labrador who came in for a left elbow arthrotomy, subtotal 
coroidectomy and left ulnar ostectomy (see Figure 9, Appendix I). He had a right subtotal 
coronoid ostectomy and an ulna ostectomy done 8 weeks before. Arthur had bilateral elbow 
dysplasia and coronoid disease. He also had hip dysplasia that luxated bilaterally previously. 
Premedication: Acepromazine 0.02 mg/kg + Methadone 0.2 mg/kg IV. Induction: Propofol 2 
mg/kg + Midazolam 0.4 mg/kg - this combination was used to reduce the dose of propofol.  
We performed a paravertebral block, which blocks the nerves which form the brachial 
plexus as they leave the spinal column. Blockade of the nerves of the brachial plexus is used in 
the management of perioperative pain in forelimb injuries and fractures. We used ultrasound to 
locate the nerves, which were blocked with ropivacaine + medetomidine. Medetomidine was 
used in combination with the local anaesthetic just in case the surgery took longer than 5 h, 
which is the duration time of ropivacaine, because it is capable of improving its intensity and 
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duration of action. Ropivacaine preferentially blocks the sensory nerves, unlike lidocaine, 
which has a more marked effect on motor nerves. Lidocaine is lipophilic, which explains why 
it can penetrate the myelin sheath around the motor nerves more easily and block them.  Risks 
of performing the block include blockade of the phrenic nerve, pneumothorax because it is too 
close to the entry of the thorax, and a sympathetic nerve block, which may result in Horner’s 
syndrome (drooping eyelid, small pupil, enophthalmos).  
We started him on ketamine CRI during surgery at 10 μg/kg/min. Ketamine was chosen 
as part of a multimodal analgesic plan, in addition to the opioid (methadone). In orthopaedic 
surgery and neurosurgery, ketamine is commonly used in combination with opioids as a part of 
a more effective approach. We administered a bolus loading dose of ketamine (0.5 mg/kg) so 
that analgesic concentrations of the drug in plasma could be achieved rapidly, then maintained 
with the CRI. We had given methadone 3 hours ago, so a further 0.1 mg/kg dose was 
administered and a dose of 0,2 mg/kg is continued post-operatively every 4 hours.  
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V - Conclusions 
The recognition and management of pain is still a subject of great investigation. The 
best principle to an effective pain management plan is understanding its pathophysiology, learn 
how to recognize the presence of pain and selecting drugs that can be applied to each procedure. 
Surgical procedures are capable of producing a great level of pain and because of that the 
perioperative period should be given special attention. Premedication and induction drugs have 
a great effect on the intra-operative surgical status of the patient and post-operative analgesia is 
essential to the healing process and well fare of the animal. Therefore, intra-operative analgesia 
should not be forgotten and analgesic options should be discussed and considered in surgical 
procedures. 
Hopefully, this thesis was capable of demonstrating the relevance of pain control in the 
operative period just like my internship at the Queen Mother Hospital for Animals reminded 
me of the importance of analgesia during that time.  
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VII - Appendix I – Figures 
 
Figure 1 - Print screen of a post from the blog about my internship (Borges 2013) 
 
Figure 2 - Types of pain. (Woolf 2010) 
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Figure 3 - Afferent fibers and pain transmission. (Lamont et al. 2000) 
 
Figure 4 - Pathways involved in nociception(Price & Nolan 2008) 
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Figure 5 - Pain sensitivity (Price & Nolan 2008) 
 
Figure 6 - Pre and post-injury analgesia (Lamont et al. 2000) 
 
 
 
 
 
 
 
Figure 7 - "Bella" (Borges 2013) 
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 - "Arthur" (Borges 2013) 
Figure 8 - Bella's porto systemic shunt surgery fluoroscopy pre and 
post shunt ligation (Borges 2013) 
